Skip to main content
AAPL-0.46%MSFT+0.82%NVDA+4.55%GOOGL-1.24%AMZN+0.96%SPCX+3.16%TSM-3.68%AVGO+2.46%META+0.61%TSLA+1.11%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.63%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.91%0700.HK-0.56%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.24%UNH-5.42%ORCL-3.38%3988.HK-0.43%BAC-1.28%HD-2.45%GE+0.38%0857.HK+0.97%1816.HK-26.34%1288.HK-0.62%0005.HK-1.62%PM-0.85%NVS-0.67%HSBA.L-1.95%INTC-0.54%MS-1.10%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.74%AUDUSD-0.67%GBPAUD+0.60%NZDJPY-0.57%NZDUSD-0.48%AUDCHF-0.45%GBPNZD+0.44%GBPTRY+0.41%AUDCAD-0.39%EURAUD+0.39%EURJPY-0.37%CADJPY-0.36%GBPHKD+0.32%CHFJPY-0.29%GBPMXN-0.28%EURUSD-0.28%USDCAD+0.28%NZDCHF-0.27%USDCHF+0.24%NZDCAD-0.22%EURGBP-0.22%GBPCAD+0.21%EURNZD+0.20%NZDMXN+0.19%GBPCHF+0.19%AUDNZD-0.18%USDTRY+0.16%USDILS+0.16%USDPLN+0.14%GBPJPY-0.14%USDMXN+0.12%USDZAR+0.11%USDTHB-0.11%NZDSGD+0.10%USDCNH-0.10%USDJPY-0.09%SGDJPY+0.09%AUDSGD-0.08%USDSEK+0.08%EURHKD-0.08%USDDKK+0.07%EURPLN+0.07%GBPZAR+0.07%USDNOK+0.06%NOKJPY+0.06%CHFSEK+0.06%AUDNOK-0.06%EURCNH-0.05%GBPUSD-0.05%EURSGD-0.04%CADCHF-0.04%USDCOP-0.04%EURCHF-0.04%AUDDKK-0.04%CHFNOK+0.03%USDSGD+0.03%EURZAR+0.02%PLNJPY-0.02%EURSEK+0.01%EURNOK-0.01%EURDKK0.00%EURCZK0.00%GBPSGD0.00%CHFSGD0.00%EURCAD0.00%USDHKD0.00%GAGUSD-1.34%XAGUSD-1.34%GAUUSD-1.09%XAUUSD-1.08%XPTUSD-0.55%W1-0.33%S1+0.29%UKOIL-0.27%USOIL-0.24%HG1+0.03%C1-0.03%XNGUSD+0.01%BTCUSD-0.66%ETHUSD+58.05%USDTUSD-0.03%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+1.09%ZECUSDT+5.27%XMRUSDT+2.59%DOGEUSD+59.04%LINKUSD+0.43%XLMUSD+1.66%BCHUSDT+0.34%LTCUSD+50.36%UNIUSD+1.19%TONUSD+63.46%SUIUSD+1.16%HBARUSDT+0.03%TAOUSDT+2.16%AAVEUSD+2.39%ONDOUSDT-0.19%ICPUSDT-8.34%DOTUSDT-0.18%WLDUSDT+0.71%ARBUSDT-0.38%INJUSDT+5.99%ATOMUSDT-1.22%STXUSDT+4.75%PYTHUSDT+0.53%TIAUSDT-1.07%FETUSDT-0.68%SEIUSDT+1.04%JUPUSDT+7.77%GRTUSDT+3.72%OPUSDT-2.36%IOTAUSDT+2.22%POLUSDT+3.14%WIFUSDT-0.31%AXSUSDT+0.23%EOSUSDT+1.77%FARTCOINUSDT-2.82%IMXUSDT+0.96%GALAUSDT-1.96%DYDXUSDT+1.60%ORDIUSDT-0.76%NOTUSDT-1.46%RONINUSDT-0.65%AAPL-0.46%MSFT+0.82%NVDA+4.55%GOOGL-1.24%AMZN+0.96%SPCX+3.16%TSM-3.68%AVGO+2.46%META+0.61%TSLA+1.11%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+4.63%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.91%0700.HK-0.56%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.24%UNH-5.42%ORCL-3.38%3988.HK-0.43%BAC-1.28%HD-2.45%GE+0.38%0857.HK+0.97%1816.HK-26.34%1288.HK-0.62%0005.HK-1.62%PM-0.85%NVS-0.67%HSBA.L-1.95%INTC-0.54%MS-1.10%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.74%AUDUSD-0.67%GBPAUD+0.60%NZDJPY-0.57%NZDUSD-0.48%AUDCHF-0.45%GBPNZD+0.44%GBPTRY+0.41%AUDCAD-0.39%EURAUD+0.39%EURJPY-0.37%CADJPY-0.36%GBPHKD+0.32%CHFJPY-0.29%GBPMXN-0.28%EURUSD-0.28%USDCAD+0.28%NZDCHF-0.27%USDCHF+0.24%NZDCAD-0.22%EURGBP-0.22%GBPCAD+0.21%EURNZD+0.20%NZDMXN+0.19%GBPCHF+0.19%AUDNZD-0.18%USDTRY+0.16%USDILS+0.16%USDPLN+0.14%GBPJPY-0.14%USDMXN+0.12%USDZAR+0.11%USDTHB-0.11%NZDSGD+0.10%USDCNH-0.10%USDJPY-0.09%SGDJPY+0.09%AUDSGD-0.08%USDSEK+0.08%EURHKD-0.08%USDDKK+0.07%EURPLN+0.07%GBPZAR+0.07%USDNOK+0.06%NOKJPY+0.06%CHFSEK+0.06%AUDNOK-0.06%EURCNH-0.05%GBPUSD-0.05%EURSGD-0.04%CADCHF-0.04%USDCOP-0.04%EURCHF-0.04%AUDDKK-0.04%CHFNOK+0.03%USDSGD+0.03%EURZAR+0.02%PLNJPY-0.02%EURSEK+0.01%EURNOK-0.01%EURDKK0.00%EURCZK0.00%GBPSGD0.00%CHFSGD0.00%EURCAD0.00%USDHKD0.00%GAGUSD-1.34%XAGUSD-1.34%GAUUSD-1.09%XAUUSD-1.08%XPTUSD-0.55%W1-0.33%S1+0.29%UKOIL-0.27%USOIL-0.24%HG1+0.03%C1-0.03%XNGUSD+0.01%BTCUSD-0.66%ETHUSD+58.05%USDTUSD-0.03%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+1.09%ZECUSDT+5.27%XMRUSDT+2.59%DOGEUSD+59.04%LINKUSD+0.43%XLMUSD+1.66%BCHUSDT+0.34%LTCUSD+50.36%UNIUSD+1.19%TONUSD+63.46%SUIUSD+1.16%HBARUSDT+0.03%TAOUSDT+2.16%AAVEUSD+2.39%ONDOUSDT-0.19%ICPUSDT-8.34%DOTUSDT-0.18%WLDUSDT+0.71%ARBUSDT-0.38%INJUSDT+5.99%ATOMUSDT-1.22%STXUSDT+4.75%PYTHUSDT+0.53%TIAUSDT-1.07%FETUSDT-0.68%SEIUSDT+1.04%JUPUSDT+7.77%GRTUSDT+3.72%OPUSDT-2.36%IOTAUSDT+2.22%POLUSDT+3.14%WIFUSDT-0.31%AXSUSDT+0.23%EOSUSDT+1.77%FARTCOINUSDT-2.82%IMXUSDT+0.96%GALAUSDT-1.96%DYDXUSDT+1.60%ORDIUSDT-0.76%NOTUSDT-1.46%RONINUSDT-0.65%

Stryker cuts 2026 outlook, shares slide 10%

NEWS

October 30, 2026 at 10:44 UTC

4 min read
Orthopedic implants in a hospital operating room reflect SYK guidance cut and 10% share slide

Key Points

  • 01Stryker (SYK) shares drop about 10% pre‑market after Q3 miss and guidance cut
  • 022026 organic sales growth outlook lowered to 6.5%–7.0% with EPS at $14.80–$14.90
  • 03Q3 organic sales grew 7.7% and adjusted EPS reached $3.52, up 10.3% year over year
  • 04Hip and knee slowdown and supply issues drive reset as Stryker (SYK) eyes 2027

Guidance cut triggers sharp share-price reaction

Stryker shares fell about 10% in pre‑market trading to $279.98 on Friday from a prior close of $311.75 after the company lowered its full‑year 2026 guidance alongside third‑quarter results. The medical device maker now expects organic net sales growth of 6.5% to 7.0% and adjusted net earnings per diluted share of $14.80 to $14.90 for 2026. The reset in outlook weighed on a stock already down roughly 20% year to date and came as a new CEO takes over leadership of the company.

Management said the updated sales guidance incorporates a modestly positive pricing impact, with foreign exchange expected to have a slightly favorable effect on both sales and adjusted earnings if rates remain near current levels. The company cut its 2026 sales guidance to 6.5%–7.0% and set adjusted EPS guidance at $14.80–$14.90.

Q3 performance: solid growth, but short of expectations

For the third quarter of 2026, Stryker reported organic sales growth of 7.7%, with revenue of $6.52 billion compared with consensus expectations of $6.62 billion. Adjusted earnings per share were $3.52 versus expectations of $3.55, but rose 10.3% from the prior year period as adjusted operating margin expanded 60 basis points to 26.2%. Management characterized the quarter as delivering good absolute performance but falling short of internal expectations.

MedSurg and Neurotechnology were key growth drivers, posting 9.1% organic sales growth, while Orthopaedics grew 5.9%. Within the U.S. market, Endoscopy organic sales increased 13%, Medical 10% and OrthoTec 18%, supported by strong demand for Mako systems and orthopedic power tools. Pricing contributed 0.1 percentage point to overall growth, and foreign currency had no impact on sales in the quarter.

Drivers of the guidance revision

Softer hip and knee procedure trends were central to the guidance revision. Management estimated hip and knee market growth at about 2.5% year to date, with Stryker’s U.S. knees up 1.3% organically and U.S. hips down 0.6%. The slowdown was linked to affordability pressures from higher insurance premiums and deductibles and increased pre‑authorization denials, as well as softer conditions in Europe and the Middle East tied to regional disruptions and funding decisions.

Lingering supply constraints in the Peripheral Vascular business and operational execution challenges from an SAP (SAPd) rollout in orthopaedics also weighed on performance. The company said inventory and product availability in affected areas improved during the quarter and are expected to continue normalizing through year‑end. Capital‑equipment demand, by contrast, remains strong, with a “strong and elevated” order book whose conversion depends on aligning manufacturing capacity with customer orders.

Positioning for 2027 from a lower base

Stryker has not issued formal 2027 guidance and plans to do so early next year, but management aims to deliver growth at the high end of its end markets while continuing to expand margins. The company indicated that its weighted average market growth rate has likely moved below the approximately 6% level discussed a year earlier, reflecting the joint‑replacement slowdown. The revised 2026 outlook therefore sets a lower starting point for planning 2027 performance.

Management pointed to a pipeline of products and strategic initiatives expected to support growth as 2027 approaches, including a powered hip solution, commercialization of AVS’s IVL platform subject to regulatory approval, new data from the PEERLESS II FlowTriever study, a next‑generation Neptune platform and a strategic investment in CMR Surgical. Stryker also highlighted its diversified portfolio and expanding Mako ecosystem as foundations for sustainable growth, while noting that formal 2027 targets will depend on evolving market conditions and procedure trends.

Capital allocation and leadership transition

During the third quarter, Stryker generated approximately $3.3 billion of year‑to‑date cash from operations and ended the period with about $3.3 billion of cash and cash equivalents. The company repurchased $1.0 billion of shares in the quarter and obtained board authorization for an additional $3.0 billion toward future buybacks, aiming to balance shareholder returns with capacity for strategic acquisitions.

The quarter also marked a leadership change, with long‑time CEO Kevin Lobo handing the role to Spencer Stiles, a nearly three‑decade company veteran. The forthcoming 2027 guidance is expected to be one of the first major milestones for the new CEO as Stryker navigates a reset in its hip and knee business while leveraging strength in MedSurg, Neurotechnology and capital equipment.

Key Takeaways

  • 01Stryker (SYK)’s 2026 guidance reset centers on slower hip and knee procedures and peripheral vascular constraints, even as overall Q3 growth and margins remained solid.
  • 02Management expects to grow at the high end of its markets in 2027 from a reduced 2026 base, but will not set formal targets until early next year.
  • 03Strong MedSurg and Neurotechnology growth, robust capital demand and a significant buyback authorization show the company leaning on diversification and capital allocation amid joint‑replacement headwinds.

Stryker cuts 2026 outlook, shares slide 10% | Trading Dashboard